Steven Greenberg,Stefano Vincenzo Gulla,Kenneth Evan Thompson
申请号：
US16306473
公开号：
US20190292264A1
申请日:
2017.06.02
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.
